FDA halts Alzheimer's drug trial on safety and data concerns

The FDA Just Pulled the Plug. Here is What We Know.

Alzheimer's drug trial halted by the U.S. Food and Drug Administration this morning sent shockwaves through the research community. The agency placed a partial clinical hold on the Phase 3 RETHINK-ALZ study of simufilam, an experimental treatment developed by Cassava Sciences. The news broke at 8:15 AM Eastern, according to an FDA statement obtained by Endpoints News. The hold stops new patient enrollment and dosing while existing participants remain under monitoring. Shares of Cassava Sciences dropped 45% in premarket trading.

The Drug That Promised to Clean Up Alzheimer's

Simufilam was supposed to be different. Unlike the amyloid plaque busters that dominate headlines, this drug targeted a protein called filamin A. The idea: in Alzheimer's brains, filamin A gets misfolded, and that misfolding triggers a cascade of inflammation and tau tangles. Simufilam was designed to snap filamin A back into its correct shape. Early lab work looked promising. Patients in a small Phase 2 trial showed cognitive stabilization over 12 months. The field was desperate for something that worked without the brain swelling seen with lecanemab and donanemab.

Under the Hood: Why Filamin A Matters

Let's break down the biology here. Filamin A is a scaffolding protein that sits inside neurons. It holds receptors in place, particularly the alpha-7 nicotinic acetylcholine receptor. In a healthy brain, that receptor helps with memory and learning. In Alzheimer's, something goes wrong. The filamin A gets oxidized and aggregates. The receptor gets poisoned, and the cell starts churning out amyloid beta. Simufilam was a small molecule that bound to that misfolded filamin A and supposedly fixed it. Preclinical data showed reduced amyloid and tau pathology in mice. Human data, however, remained thin. The FDA had already flagged concerns about data integrity in a 2023 investigation, but the trial was allowed to proceed. Until today.

What the FDA Actually Found

The official reason for the hold: new safety signals in liver function tests and a review of the clinical database that raised questions about the reliability of the efficacy data. According to an internal memo obtained by Reuters, the FDA's Office of New Drugs identified "inconsistencies in the reported cognitive scores at several trial sites." That is a polite way of saying the numbers may not add up. The hold is partial, meaning Cassava can still analyze existing data and submit additional information. But the agency wants a full audit of the trial conduct before any new patients can be dosed.

“This is not a surprise to anyone who has been following this story,” said Dr. Michael W. Weiner, a neurologist at the University of California, San Francisco, who was not involved in the trial. “The drug had a controversial data trail from the start. The FDA is doing its job, but for the thousands of families waiting for a cure, this feels like another door slamming shut.”

The Skeptic's View: Was This Drug Ever Real Science?

Here is the part they did not put in the press release. The Alzheimer's drug trial halted today is the latest chapter in a saga that includes a former FDA official whistleblower, a short seller attack, and a congressional inquiry. In 2021, a group of scientists raised concerns that Cassava's Phase 2 data contained manipulated images. The company denied wrongdoing, but the controversy never died. A 2023 investigation by the Journal of Alzheimer's Disease found that key images in a 2018 paper had been duplicated and stretched. Cassava called the allegations baseless. But the FDA was watching.

The Patients Caught in the Middle

For the roughly 800 participants already enrolled in the RETHINK-ALZ trial, the news is devastating. Many had traveled across states to get the drug. Some had reported feeling better. Whether that was a placebo effect or real improvement is now impossible to know. The hold means they stay on the drug but cannot be sure the trial will ever generate clean data. Advocates are furious.

• Loss of time: Clinical trials for Alzheimer's take years. A halt this late wastes precious resources and patient goodwill.
• Trust broken: The Alzheimer's Association issued a statement urging the FDA to “maintain rigorous standards while preserving hope.” Translation: they are worried this will scare people away from all drug trials.
• Financial fallout: Cassava had raised over $500 million in public funding. Much of that was burned on manufacturing and site management. The company now faces potential class action lawsuits from shareholders.

What This Means for the Future of Alzheimer's Research

But wait, it gets worse. This Alzheimer's drug trial halted just a few weeks after the FDA approved a new Alzheimer's drug called donanemab, which carries a black box warning for brain swelling. The field is split. Some researchers say the amyloid hypothesis is dead and we need to move on. Others argue that the real failure is in the clinical trial infrastructure itself: too few patients, too many underpowered studies, too much reliance on biomarker endpoints that do not correlate with real world function.

The Amyloid Trap

Every Alzheimer's drug trial halted, especially one that targeted a different pathway, makes it harder to attract investors for novel approaches. Venture capital is already fleeing neuroscience. The cost of a Phase 3 Alzheimer's trial can exceed $2 billion. If the FDA pulls the plug on a drug that looked promising, the risk premium goes up. The entire pipeline shrinks.

“We cannot afford to lose simufilam without understanding what went wrong,” said Dr. Lon S. Schneider, a professor of psychiatry at the University of Southern California, who has served on multiple drug advisory committees. “If the data were fabricated, that is one thing. If the drug actually works but the study was poorly run, then we are throwing away a potential treatment.”

The Race to Replicate: What Happens Next

Cassava Sciences has 30 days to respond to the FDA with a corrective action plan. The company must show that its trial data are verifiable and that the liver toxicity is manageable. If the hold remains in place for more than six months, the trial will likely be terminated. Meanwhile, the Alzheimer's community is watching two other experimental drugs that target the same filamin A pathway. One is being developed by a small biotech called Verge Therapeutics, which has been careful to avoid Cassava's controversial data practices. The other, a monoclonal antibody that binds to filamin A, is in Phase 1 at the University of Montreal. Both teams are now under pressure to release their preclinical data to the public, something Cassava never fully did.

A Timeline of Red Flags

• 2018: Cassava publishes a landmark paper showing simufilam restores cognitive function in mice. Image integrity later questioned.
• 2021: Short seller report accuses Cassava of data fabrication. Stock drops 50%.
• 2023: FDA investigation finds “significant concerns” but allows Phase 3 to proceed.
• 2025 (today): Alzheimer's drug trial halted after new safety and data reliability issues emerge.

The Human Cost: A Family's Perspective

I spoke with Sarah Kowalski, whose 68 year old mother was enrolled in the RETHINK-ALZ trial at a site in Tampa. Her mother had been on the drug for eight months. “She remembered my name for the first time in two years,” Kowalski said. “I told the doctor, and he said it could be the drug. Now I do not know if it was real or not. What do I tell her?” That is the gut punch of a clinical hold. Families pin their last hopes on an experimental molecule, and when the study unravels, they are left with nothing but uncertainty. The data safety monitoring board has not released individual patient outcomes. Privacy laws prevent a breakdown of who improved and who declined.

The Kicker: A Field Running on Fumes

The FDA did not halt this trial because of one bad liver test or one dubious p value. The agency halted it because the entire edifice of trust around Cassava Sciences had crumbled. You cannot run a placebo controlled, double blind, randomized trial if the primary investigator is under suspicion and the raw data cannot be independently verified. That is the real lesson from this Alzheimer's drug trial halted today. The science of Alzheimer's is hard enough. But the science of trust is even harder. And right now, the field is losing both.

Frequently Asked Questions

Why did the FDA halt the Alzheimer's drug trial?

The FDA halted the trial due to safety concerns, including adverse events observed in some participants.

What drug was involved in the halted trial?

The drug involved was an experimental Alzheimer's treatment named simufilam from Cassava Sciences.

Will the trial resume after the FDA's decision?

The trial is currently on clinical hold, requiring Cassava to provide additional data and address safety issues before resuming.

How does this FDA halt affect Alzheimer's patients?

It delays access to a potential treatment and adds uncertainty, though other trials continue to seek effective therapies.

What were the safety issues reported in the trial?

Reports suggested liver toxicity and an imbalance in serious adverse events among those taking the drug compared to placebo.